CytomX Therapeutics, Inc. Expands Series B Financing; Canaan Partners Joins Syndicate
Published: Jul 31, 2012
SAN FRANCISCO--(BUSINESS WIRE)--CytomX Therapeutics, Inc., a biotechnology company creating a new generation of highly targeted antibody therapeutics, today announced that the company has expanded its Series B financing, bringing the total size of the round to $41 million. Canaan Partners led the financing and was joined by existing investors Third Rock Ventures and the Roche Venture Fund. In conjunction with the financing, Tim Shannon, M.D., of Canaan Partners will join CytomX’s board of directors.